PharmAust Limited (ASX: PAA & PAAOA) is excited to share positive interim study results from the ongoing Open Label Extension Study in ALS. Treatment with monepantel continues to be well-tolerated, slowing disease progression and improving survival. Compared to untreated controls, patients showed significantly increased survival, reduced risk of death by 80.3%, and a 43.2% decrease in ALS functional decline. Some patients have now entered their 23rd month of treatment with MPL.<br/><br/>The ongoing study is progressing well, with encouraging results indicating MPL's potential to improve life expectancy in ALS patients. The Phase 2/3 study of MPL in the HEALEY ALS Platform Trial is expected to enroll next quarter. <br/><br/>Despite an unsuccessful FightMND grant application, MPL's selection for the HEALEY ALS Platform Trial offers significant financial advantages and an accelerated pathway to bring MPL to all patients. <br/><br/>For further details and inquiries, contact us or visit our Investor Hub for more information. We invite investors to engage with us and look forward to answering any questions you may have. Our commitment to advancing treatments for neurodegenerative diseases remains unwavering.